Abstract 18947: Sirolimus-eluting Stent versus Non-Sirolimus Drug-eluting Stents in ‘Real World’ Unprotected Left Main Intervention
Backgrouds: Sirolimus-eluting stent (SES; Cypher) has recently been known to be related to profound delayed healing and better angiographic outcomes compared with those of non-sirolimus drug-eluting stents (DES). We compared the safety and efficacy of SES with those of other DESs in unprotected left main (LM) angioplasty up to 12 months.
Methods: All patients (pts) with unprotected LM regardless of LV dysfunction were electively treated with sirolimus-(SES; Cypher), paclitaxel-(PES; Taxus), zotarolimus- (ZES; Endeavor) or everolimus-eluting stents (EES; Xience). LM bifurcation lesions were treated by kissing stenting, crushing technique or stent crossover (Stent/Balloon). Six months angiographic outcomes and twelve months clinical outcomes were compared between the two groups.
Results: Out of total 131 pts (Male 75, mean age, 63.61±11.37 years) underwent percutaneous coronary intervention (PCI) with DES on unprotected LM lesion, 75 pts (75/135, 57.3%) were exclusively treated with SES, 56 pts (56/131, 42.7%) with non-SES (35 PES, 15 ZES, 6 EES). At 12 months, clinical and angiographic follow up results showed no significant differences between the groups except higher incidence of stent thrombosis in the SES group (Table).
Conclusions: Both SES and non-SES implantation in unprotected LM showed similar clinical and angiographic outcomes up to 12 months, however, safety concerning is still noted in the SES group due to higher incidence of stent thrombosis with the time.
- © 2010 by American Heart Association, Inc.